Confo Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- Confo Therapeutics's estimated annual revenue is currently $12.2M per year.
- Confo Therapeutics's estimated revenue per employee is $155,000
Employee Data
- Confo Therapeutics has 79 Employees.
- Confo Therapeutics grew their employee count by 0% last year.
Confo Therapeutics Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $5M | 32 | -26% | N/A | N/A |
#2 | $510.1M | 1097 | 31% | $2B | N/A |
#3 | $13.6M | 88 | 44% | N/A | N/A |
#4 | $12.2M | 79 | 0% | N/A | N/A |
#5 | $28.7M | 185 | 5% | N/A | N/A |
#6 | $35.2M | 227 | 8% | N/A | N/A |
#7 | $4M | 26 | -10% | N/A | N/A |
#8 | $10.9M | 70 | 23% | N/A | N/A |
#9 | $10.4M | 67 | 24% | N/A | N/A |
#10 | $6.2M | 40 | 29% | N/A | N/A |
What Is Confo Therapeutics?
Confo Therapeutics is an emerging drug discovery company built around a disruptive technology to enable the discovery of GPCR agonists. The CONFO® technology uses single domain antibodies to lock inherently unstable GPCRs in the druggable conformation and uses this stabilized complex as a superior starting point for GPCR drug discovery. The company's strategy is to broadly exploit its technology by building a unique portfolio of therapeutic programs in various disease areas, both for its own pipeline as well as with pharma partners. For more information: www.confotherapeutics.com
keywords:N/A
N/A
Total Funding
79
Number of Employees
$12.2M
Revenue (est)
0%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Confo Therapeutics News
Confo Therapeutics' unparalleled technology stabilizes functional conformations of GPCRs (G protein-coupled receptors) to uncover a wide range...
Confo Therapeutics today announces that it has been awarded a €1.7 million grant from Flanders Innovation & Entrepreneurship (VLAIO). The grant will run over two years and will support one of the Company’s proprietary pre-clinical programs, targeting a neurological orphan indication. The grant w ...
Confo Therapeutics, a Ghent, Belgium-based drug discovery company, completed a €30m ($33.4m) Series A financing. The round was led by BioGeneration Ventures (BGV) and co-led by Wellington Partners, with participation from new investors Fund+ and Perceptive Advisors and existing investors Capric ...
Confo Therapeutics has raised €30 million ($34 million) to take compounds targeting difficult-to-drug GPCRs into clinical development. The series A round (PDF) sets Confo up to advance drugs derived from a novel way of stabilizing GPCRs and performing more sensitive screens. Sponsored by Agilen ...
Other Companies in Zwijnaarde
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $12.2M | 79 | 7% | N/A |
#2 | $61.7M | 159 | 7% | N/A |
#3 | $57.6M | 194 | 22% | N/A |
#4 | $510.1M | 1097 | 31% | $2B |